Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A

Inclusion Criteria:

- Informed consent obtained before any study-related activities. Study-related
activities are any procedure related to recording of data according to the protocol

- Previously FVIII treated (150 exposure days at the time of first dosing with
turoctocog alfa) male patients with the diagnosis of severe and moderately severe
haemophilia A (FVIII below or equal to 2%)

- The decision to initiate treatment with commercially available turoctocog alfa has
been made by the patient/parent and the patient's treating physician before and
independently from the decision to include the patient in this study

- A negative FVIII inhibitor test obtained not more than four weeks prior to first
dosing with turoctocog alfa

Exclusion Criteria:

- Contraindications for use according to the approved product information text (US
Package insert (PI), European Summary of Product Characteristics (SmPC), or
corresponding local prescribing information)

- Treatment with any investigational drug within 30 days prior to enrolment into the
study

- Previous participation in any clinical trial with turoctocog alfa

- Treatment with other FVIII products after initiation of treatment with turoctocog alfa